Embedded Player Pfizer Inc. halts tests of a highly touted new cholesterol drug because of an unexpected number of deaths and other complications. Testing on the drug, torcetrapib, was ceased after more people in the drug group died than in the placebo group. The drug was unique in that it raises HDL, the "good" kind of cholesterol.